2025-03-31 18:35:06
Latest Post
NHPC commissions 3 units of Parbati-II HE project
ixigo announces APRIL FULL REFUND SALE for 1st April - 100 Lucky Travellers To Win 100% Refund on Flight Bookings
Engineers India Ltd receives orders worth Rs. 245 crores
Blue Star appoints Mohit Sud as Group President, Unitary Cooling Products 
Jyoti Ltd receives Rs. 108.17 crores IT demand notice for AY 2020-21
Stock Report
Jenburkt Pharmaceuticals Ltd Q2 FY2023 profit up QoQ at Rs. 6.86 crores
Posted On : 2022-11-08 21:37:28( TIMEZONE : IST )
JENBURKT PHARMACEUTICALS LTD. has reported Standalone financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 37.1136 crores during the period ended September 30, 2022 as compared to Rs. 32.2745 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. 6.8662 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. 5.9532 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. 14.96 for the period ended September 30, 2022 as compared to Rs. 12.97 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 37.1136 crs | ₹32.2745 crs |  14.99% |
| Net Profit | ₹6.8662 crs | ₹5.9532 crs | 15.34% |
| EPS | ₹14.96 | ₹12.97 | 15.34% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 37.1136 crores during the period ended September 30, 2022 as compared to Rs.36.6990 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.6.8662 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.7.9704 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.14.96 for the period ended September 30, 2022 as compared to Rs.17.37 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 37.1136 crs | ₹36.6990 crs | 1.13% |
| Net Profit | ₹6.8662 crs | ₹7.9704 crs |  -13.85% |
| EPS | ₹14.96 | ₹17.37 | -13.87% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.69.3881 crores during the 6 Months period ended September 30, 2022 as compared to Rs.65.0737 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.12.8194 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.12.6213 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.27.93 for the 6 Months period ended September 30, 2022 as compared to Rs.27.50 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹69.3881 crs | ₹65.0737 crs | 6.63% |
| Net Profit | ₹12.8194 crs | ₹12.6213 crs | 1.57% |
| EPS | ₹27.93 | ₹27.50 | 1.56% |
Shares of JENBURKT PHARMACEUTICALS LTD. was last trading in BSE at Rs. 585.60 as compared to the previous close of Rs. 579.20. The total number of shares traded during the day was 10943 in over 89 trades.
The stock hit an intraday high of Rs. 597.00 and intraday low of 585.50. The net turnover during the day was Rs. 6460658.00.
